Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBlueprint Medicines Corporation

About this trial

This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.

Eligibility criteria

Qualifiers

Documented anaphylaxis due to Hymenoptera venom with cardiovascular symptoms or

History of at least one event of anaphylaxis as determined by the Investigator's clinical assessment and judgment based on available medical history, clinical presentation, and supporting documentation without a clearly identifiable trigger(s) or allergen(s) (otherwise idiopathic anaphylaxis) OR

SMAC-AGS: History of anaphylaxis after eating mammalian meat (e.g. pork, beef) AND history of elevated alpha-gal (galactose-alpha 1, 3 galactose) serum IgE as determined by the Investigator's clinical assessment and supporting medical history documentation 2. SMAC-B

Episodic or recurrent signs and symptoms consistent with mast cell activation without known triggers or allergens in at least 2 of the following organ systems: skin, respiratory/naso-ocular, gastrointestinal tract, or cardiovascular.

Disqualifiers

Monoclonal mast cell activation syndrome with a known KIT mutation

Any subtype of systemic mastocytosis

Mast cell sarcoma

Cohort 2 only: Osteopenia or osteoporosis attributed to known genetic, endocrine, nutritional, or other medical conditions.

Trial design

Treatments tested in this trial

  • Screening

Treatment groups

750 Participants
are divided into 4 treatment groups